Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. NativeMed LLC dba NativeMed
WARNING LETTER
•NativeMed LLC dba NativeMed•March 1, 2026

NativeMed LLC dba NativeMed – FDA Warning Letter, Mar 1, 2026

Record Details

On June 8, 2026, the FDA issued a warning letter to NativeMed LLC, doing business as NativeMed, following a March 2026 review of the company’s website. The investigation revealed significant violations of the Federal Food, Drug, and Cosmetic Act regarding the sale of compounded semaglutide and tirzepatide products. The FDA determined that NativeMed’s promotional materials were false and misleading, resulting in the products being classified as misbranded. Key violations included the use of NativeMed’s logo on labels for tirzepatide, which incorrectly identified the company as the manufacturer. Additionally, the website claimed its compounded semaglutide contained the "same active ingredient" as FDA-approved medications like Ozempic and Wegovy. The FDA clarified that compounded drugs are not FDA-approved, and such claims suggest a level of safety and efficacy evaluation that has not occurred. Under the current regulatory framework, specifically sections 502(a) and 502(bb), these representations are prohibited. NativeMed is required to respond within 15 business days with a comprehensive plan to address these violations. Required actions include identifying the actual producers of the drugs, providing updated labeling samples, and modifying or removing misleading website content. Failure to implement sustained corrective measures may lead to legal consequences, such as product seizures or court-ordered injunctions.

Company
NativeMed LLC dba NativeMed
Inspection date
March 1, 2026
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Matthew J. Lash (Acting Director)
View Company Profile

ID · 975f08c3-2ce5-46a3-8e6a-d615b07ae5dc

Violation Codes10
FD&C Act 502(a)21 U.S.C. 352(a)FD&C Act 201(p)(1)FD&C Act 201(g)(1)21 U.S.C. 321(g)(1)21 U.S.C. 353a21 U.S.C. 331(c)21 U.S.C. 353(b)(1)FD&C Act 503(b)(1)21 U.S.C. 353b

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore NativeMed LLC dba NativeMed
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.